Futura Medical Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Futura Medical has been growing earnings at an average annual rate of 6.8%, while the Pharmaceuticals industry saw earnings declining at 5.2% annually. Revenues have been growing at an average rate of 93.3% per year.

Anahtar bilgiler

6.8%

Kazanç büyüme oranı

19.2%

EPS büyüme oranı

Pharmaceuticals Sektör Büyümesi14.1%
Gelir büyüme oranı93.3%
Özkaynak getirisi-48.1%
Net Marj-44.7%
Son Kazanç Güncellemesi30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)

Sep 13
Need To Know: Analysts Are Much More Bullish On Futura Medical plc (LON:FUM)

We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth

Apr 17
We Think Futura Medical (LON:FUM) Can Easily Afford To Drive Business Growth

Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation

Jan 05
Here's Why We're Not At All Concerned With Futura Medical's (LON:FUM) Cash Burn Situation

Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?

Jul 28
Is Futura Medical (LON:FUM) In A Good Position To Invest In Growth?

We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully

Mar 18
We Think Futura Medical (LON:FUM) Needs To Drive Business Growth Carefully

We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate

Sep 25
We're Keeping An Eye On Futura Medical's (LON:FUM) Cash Burn Rate

Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation

May 10
Here's Why We're Not Too Worried About Futura Medical's (LON:FUM) Cash Burn Situation

We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow

Jan 10
We're Interested To See How Futura Medical (LON:FUM) Uses Its Cash Hoard To Grow

What We Learned About Futura Medical's (LON:FUM) CEO Compensation

Dec 21
What We Learned About Futura Medical's (LON:FUM) CEO Compensation

Gelir ve Gider Dağılımı

Futura Medical nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.


Kazanç ve Gelir Geçmişi

AIM:FUM Gelir, gider ve kazançlar (GBP Millions )
TarihGelirKazançlarG+A GiderleriAr-Ge Giderleri
30 Jun 248-482
31 Mar 246-572
31 Dec 233-772
30 Sep 232-653
30 Jun 232-543
31 Mar 231-534
31 Dec 220-634
30 Sep 220-634
30 Jun 220-624
31 Mar 220-524
31 Dec 210-524
30 Sep 210-423
30 Jun 210-312
31 Mar 210-312
31 Dec 200-212
30 Sep 200-414
30 Jun 200-616
31 Mar 200-718
31 Dec 190-9110
30 Sep 190-9110
30 Jun 190-819
31 Mar 190-718
31 Dec 180-616
30 Sep 180-515
30 Jun 180-414
31 Mar 180-414
31 Dec 170-414
30 Sep 170-414
30 Jun 170-313
31 Mar 170-413
31 Dec 160-414
30 Sep 160-414
30 Jun 160-514
31 Mar 160-514
31 Dec 150-515
30 Sep 150-514
30 Jun 150-414
31 Mar 150-413
31 Dec 140-312
30 Sep 140-312
30 Jun 140-312
31 Mar 140-212
31 Dec 130-212

Kaliteli Kazançlar: FUM is currently unprofitable.

Büyüyen Kar Marjı: FUM is currently unprofitable.


Serbest Nakit Akışı ve Kazanç Analizi


Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: FUM is unprofitable, but has reduced losses over the past 5 years at a rate of 6.8% per year.

Büyüme Hızlandırma: Unable to compare FUM's earnings growth over the past year to its 5-year average as it is currently unprofitable

Kazançlar vs. Sektör: FUM is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


Özkaynak Getirisi

Yüksek ROE: FUM has a negative Return on Equity (-48.05%), as it is currently unprofitable.


Varlık Getirisi


Kullanılan Sermaye Getirisi


Geçmişte güçlü performans gösteren şirketleri keşfedin